Migraine - Pipeline Review, H2 2017

Date: October 31, 2017
Pages: 201
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: ME908B37F02EN
Leaflet:

Download PDF Leaflet

Migraine - Pipeline Review, H2 2017
Migraine - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H2 2017, provides an overview of the Migraine (Central Nervous System) pipeline landscape.

Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Migraine - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 12, 14, 12, 21, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Migraine - Overview
Migraine - Therapeutics Development
Migraine - Therapeutics Assessment
Migraine - Companies Involved in Therapeutics Development
Migraine - Drug Profiles
Migraine - Dormant Projects
Migraine - Discontinued Products
Migraine - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Migraine, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd.1), H2 2017
Products under Development by Companies, H2 2017 (Contd.2), H2 2017
Products under Development by Companies, H2 2017 (Contd.3), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd.1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Migraine - Pipeline by 4P Therapeutics LLC, H2 2017
Migraine - Pipeline by Achelios Therapeutics Inc, H2 2017
Migraine - Pipeline by Acorda Therapeutics Inc, H2 2017
Migraine - Pipeline by Alder Biopharmaceuticals Inc, H2 2017
Migraine - Pipeline by Allergan Plc, H2 2017
Migraine - Pipeline by Amgen Inc, H2 2017
Migraine - Pipeline by Aralez Pharmaceuticals Inc, H2 2017
Migraine - Pipeline by Astellas Pharma Inc, H2 2017
Migraine - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
Migraine - Pipeline by Biofrontera AG, H2 2017
Migraine - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H2 2017
Migraine - Pipeline by BioHealthonomics Inc, H2 2017
Migraine - Pipeline by Charleston Laboratories Inc, H2 2017
Migraine - Pipeline by Corium International Inc, H2 2017
Migraine - Pipeline by Crossject SA, H2 2017
Migraine - Pipeline by Eli Lilly and Co, H2 2017
Migraine - Pipeline by Impel NeuroPharma Inc, H2 2017
Migraine - Pipeline by InKemia IUCT Group SA, H2 2017
Migraine - Pipeline by InStar Technologies AS, H2 2017
Migraine - Pipeline by Insys Therapeutics Inc, H2 2017
Migraine - Pipeline by IntelGenx Corp, H2 2017
Migraine - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Migraine - Pipeline by Klaria Pharma Holding AB, H2 2017
Migraine - Pipeline by Monosol Rx LLC, H2 2017
Migraine - Pipeline by NAL Pharmaceuticals Ltd, H2 2017
Migraine - Pipeline by Pharmaleads SA, H2 2017
Migraine - Pipeline by Promius Pharma LLC, H2 2017
Migraine - Pipeline by Q BioMed Inc, H2 2017
Migraine - Pipeline by Revance Therapeutics Inc, H2 2017
Migraine - Pipeline by Shin Nippon Biomedical Laboratories Ltd, H2 2017
Migraine - Pipeline by Suda Ltd, H2 2017
Migraine - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
Migraine - Pipeline by TheraJect Inc, H2 2017
Migraine - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017
Migraine - Pipeline by Trevena Inc, H2 2017
Migraine - Pipeline by Trigemina Inc, H2 2017
Migraine - Pipeline by TrioxBio Inc, H2 2017
Migraine - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
Migraine - Pipeline by Xenon Pharmaceuticals Inc, H2 2017
Migraine - Pipeline by Zosano Pharma Corp, H2 2017
Migraine - Dormant Projects, H2 2017
Migraine - Dormant Projects, H2 2017 (Contd.1), H2 2017
Migraine - Dormant Projects, H2 2017 (Contd.2), H2 2017
Migraine - Dormant Projects, H2 2017 (Contd.3), H2 2017
Migraine - Dormant Projects, H2 2017 (Contd.4), H2 2017
Migraine - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Migraine, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

4P Therapeutics LLC
Achelios Therapeutics Inc
Acorda Therapeutics Inc
Alder Biopharmaceuticals Inc
Allergan Plc
Amgen Inc
Aralez Pharmaceuticals Inc
Astellas Pharma Inc
Avanir Pharmaceuticals Inc
Biofrontera AG
Biohaven Pharmaceutical Holding Company Ltd
BioHealthonomics Inc
Charleston Laboratories Inc
Corium International Inc
Crossject SA
Eli Lilly and Co
Impel NeuroPharma Inc
InKemia IUCT Group SA
InStar Technologies AS
Insys Therapeutics Inc
IntelGenx Corp
Ionis Pharmaceuticals Inc
Klaria Pharma Holding AB
Monosol Rx LLC
NAL Pharmaceuticals Ltd
Pharmaleads SA
Promius Pharma LLC
Q BioMed Inc
Revance Therapeutics Inc
Shin Nippon Biomedical Laboratories Ltd
Suda Ltd
Teva Pharmaceutical Industries Ltd
TheraJect Inc
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Trigemina Inc
TrioxBio Inc
Vertex Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
Zosano Pharma Corp
Skip to top


NeurAxon, Inc. - Product Pipeline Review - 2014 US$ 1,500.00 Sep, 2014 · 23 pages

Ask Your Question

Migraine - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: